Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on November 5, 2024. The filing addresses a change in the company's independent registered public accounting firm. Note: The request metadata lists "Bio Green Med Solution, Inc.", but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure regarding corporate governance and audit oversight.
Material Changes
- Dismissal of Auditor: The Audit Committee dismissed Crowe LLP as the independent registered public accounting firm, effective November 5, 2024. Crowe was engaged on August 19, 2024, but had not yet issued an audit report.
- Engagement of New Auditor: The Audit Committee engaged Bush & Associates CPA LLP ("Bush") as the new independent registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately.
- Reportable Event: Crowe advised the Company that certain provisions of warrants issued in the April 2024 Securities Purchase Agreement (and potentially prior agreements) might preclude equity classification. Crowe noted that further investigation into this matter might materially impact the fairness of the financial statements, but the investigation was not completed due to their dismissal.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future operations. The primary risk disclosed is the potential material impact on the fairness of financial statements regarding the classification of warrants issued in April 2024 and potentially prior periods. The company has authorized the new auditor, Bush, to investigate this matter fully.
Investor Verification Checklist
- Verify the status of the warrant classification issue raised by Crowe LLP and its potential impact on the balance sheet and equity.
- Confirm the timeline for the new auditor (Bush & Associates CPA LLP) to complete their review and issue an opinion.
- Review the letter from Crowe LLP (Exhibit 16.1) for any additional details on the reportable event.
- Monitor future filings for the resolution of the accounting disagreement regarding warrant equity classification.